Live Breaking News & Updates on Central Ethics

Stay updated with breaking news from Central ethics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Nzimande: Get OUTA here or I'll sue!

This was the response from Higher Education Minister Blade Nzimande against allegations that he was corrupt. ....

South Africa , South Africans , South African , Blade Nzimande , Ernest Khosa , African Communist Party , Services Sector Education , National Student Financial Aid Scheme Nsfas , African Nation Congress Integrity Commission , Central Ethics Commission , Organisation Undoing Tax Abuse Outa , Training Authority , Higher Education Minister Blade Nzimande , Organisation Undoing Tax Abuse , National Student Financial Aid Scheme , Nsfas Mr Khosa , African Nation Congress , Integrity Commission , South African Communist Party , Central Ethics ,

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Pawel Przewiezlikowski , Central Ethics Committee , Drug Administration , Warsaw Stock Exchange , Leukemia Lymphoma Society Therapy Acceleration Program , Menarini Group , Congress On , Office For Registration Of Medicinal Products , Chief Executive Officer , Serious Adverse Event , Clinical Trial Application , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , Central Ethics , Lymphoma Society Therapy Acceleration Program , ஒன்றுபட்டது மாநிலங்களில் , மைய நெறிமுறைகள் குழு , வார்சா ஸ்டாக் பரிமாற்றம் , லுகேமியா லிம்போமா சமூகம் சிகிச்சை விரைவுபடுத்துதல் ப்ரோக்ர்யாம் , காங்கிரஸ் ஆன் , அலுவலகம் க்கு பதிவு ஆஃப் மருத்துவ ப்ராடக்ட்ஸ் , தலைமை நிர்வாகி அதிகாரி , மருத்துவ சோதனை விண்ணப்பம் ,

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
News provided by
Share this article
Share this article
KRAKOW, Poland, May 28, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that its Clinical Trial Application (CTA) to commence a single-agent, open-label Phase I/II trial, investigating the safety and efficacy of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland, has been fully approved by the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, and the respective Central Ethics Committee. ....

United States , Setareh Shamsili , Central Ethics Committee , Leukemia Lymphoma Society Therapy Acceleration Program , Menarini Group , Drug Administration , Warsaw Stock Exchange , Office For Registration Of Medicinal Products , Ryvu Therapeutics , Clinical Trial Application , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , Central Ethics , Triple Negative Breast Cancer , Chief Medical Officer , Clinical Trial Applications , Lymphoma Society Therapy Acceleration Program , ஒன்றுபட்டது மாநிலங்களில் , மைய நெறிமுறைகள் குழு , லுகேமியா லிம்போமா சமூகம் சிகிச்சை விரைவுபடுத்துதல் ப்ரோக்ர்யாம் , வார்சா ஸ்டாக் பரிமாற்றம் , அலுவலகம் க்கு பதிவு ஆஃப் மருத்துவ ப்ராடக்ட்ஸ் , மருத்துவ சோதனை விண்ணப்பம் , போலீஷ அலுவலகம் ,

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Setareh Shamsili , Central Ethics Committee , Leukemia Lymphoma Society Therapy Acceleration Program , Menarini Group , Drug Administration , Warsaw Stock Exchange , Office For Registration Of Medicinal Products , Ryvu Therapeutics , Clinical Trial Application , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , Central Ethics , Triple Negative Breast Cancer , Chief Medical Officer , Clinical Trial Applications , Lymphoma Society Therapy Acceleration Program , ஒன்றுபட்டது மாநிலங்களில் , மைய நெறிமுறைகள் குழு , லுகேமியா லிம்போமா சமூகம் சிகிச்சை விரைவுபடுத்துதல் ப்ரோக்ர்யாம் , வார்சா ஸ்டாக் பரிமாற்றம் , அலுவலகம் க்கு பதிவு ஆஃப் மருத்துவ ப்ராடக்ட்ஸ் , மருத்துவ சோதனை விண்ணப்பம் , போலீஷ அலுவலகம் ,

Ryvu Therapeutics Reports First Quarter 2021 Financial Results

Ryvu Therapeutics Reports First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
KRAKOW, Poland, May 12, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU) reported today its first quarter 2021 financial results and provided a corporate update.
Q1 2021 was an eventful quarter for Ryvu and developments around RVU120 played a key role in it - commented Pawel Przewiezlikowski, Chief Executive Officer of Ryvu. We have submitted a clinical trial application to conduct a Phase I/II study of RVU120 in patients with solid tumors, and shortly after that we received an approval to expand the ongoing Phase I of RVU120 in AML and high risk MDS from US sites to Poland. We have also secured a non-dilutive grant to finance the RVU120 solid tumor study. Despite the recent partial clinical hold imposed on RVU120 Phase Ib study, we have achieved meaningful research progress in our clinical and pre-clinical pipeline in these first months of 2 ....

United States , Pawel Przewiezlikowski , Central Ethics Committee , National Center , Drug Administration , American Association Of Cancer Research , Warsaw Stock Exchange , Stock Exchange Company Of The Year , Development Ncbi , Warsaw Stock Exchange Company Of The Year , Office For Registration , Services Innovation , Office For Registration Of Medicinal Products , Chief Executive Officer , Clinical Trial Application , Polish Office , Medicinal Products , Medical Devices , Biocidal Products , Central Ethics , Ryvu Therapeutics , Acute Myeloid Leukemia , High Risk Myelodysplastic Syndrome , Warsaw Stock Exchange Company , Stock Exchange Company , American Association ,